sciclone pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : sciclone pharmaceuticals

SCLN 11.15

0.0%

Oct 20 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: JEB who wrote (895)	8/22/2001 8:12:05 PM
From: Oak Tree	Read Replies (3) of 1137

Attached is the original article. ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11432891&dopt=Abstract I was referring to one that can't be gotten on the internet in which they did a proper study in which they treated maximally responding patients with additional chemo plus C225 and found that many of the patients appeared to respond more. In that study none of the patients got a Complete response since they were treating recurrent patients. The study abstract for C225 seriously misstates the facts regarding the complete response rate to radiation and to standard radiation with chemotherapy. The big difference being the initial response rates are excellent -- its just that when it comes back things are bad. The response rate is actually expected to be nearly 100% and the CR rate is likewise expected to be 80%. For example: ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10924966&dopt=Abstract Especially if the radiation is given twice a day as it was in about 20% of the patients in the C225 study. ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11367897&dopt=Abstract ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10924966&dopt=Abstract The effect was the radiation not the C225. In fact the above studies that feature advanced patients all had similar or better median survivals than the C225 study.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next